The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 11, 2014
Filed:
Jun. 02, 2008
Liming Shao, Lincoln, MA (US);
Fengjiang Wang, Northborough, MA (US);
Scott Christopher Malcolm, Southborough, MA (US);
Michael Charles Hewitt, Somerville, MA (US);
Jianguo MA, Natick, MA (US);
Seth Ribe, Worcester, MA (US);
Mark A. Varney, Laguna Nigel, CA (US);
Una Campbell, Marlborough, MA (US);
Sharon Rae Engel, Hudson, MA (US);
Larry Wendell Hardy, Sturbridge, MA (US);
Patrick Koch, Marlborough, MA (US);
Rudy Schreiber, Watertown, MA (US);
Kerry L. Spear, Concord, MA (US);
Liming Shao, Lincoln, MA (US);
Fengjiang Wang, Northborough, MA (US);
Scott Christopher Malcolm, Southborough, MA (US);
Michael Charles Hewitt, Somerville, MA (US);
Jianguo Ma, Natick, MA (US);
Seth Ribe, Worcester, MA (US);
Mark A. Varney, Laguna Nigel, CA (US);
Una Campbell, Marlborough, MA (US);
Sharon Rae Engel, Hudson, MA (US);
Larry Wendell Hardy, Sturbridge, MA (US);
Patrick Koch, Marlborough, MA (US);
Rudy Schreiber, Watertown, MA (US);
Kerry L. Spear, Concord, MA (US);
Sunovion Pharmaceuticals Inc., Marlborough, MA (US);
Abstract
Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.